Occupational Therapists in South Boston, MA Accepting Medicare
6 Occupational Therapists found. Showing 1 - 6
 Mrs. Kristin Heather Tinlin Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 602 E 5th St, South Boston, MA 02127 Phone: 617-269-5039 |
Kerry Anne Hannigan, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 59 W 7th St, South Boston, South Boston, MA 02127 Phone: 310-433-4245 |
Dr. Micaela Hill, OTD, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2 Lovis St, South Boston, MA 02127 Phone: 352-206-8040 |
 Advanced Ot Of Boston Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 167 M St Apt 1f, South Boston, MA 02127 Phone: 310-433-4245 |
Eva Marie Kolman, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 664 Dorchester Ave, South Boston, MA 02127 Phone: 617-267-3700 |
A Spot Of Therapy Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 308 K St, South Boston, MA 02127 Phone: 818-606-8673 |
News Archive
Loyola's Neil Gupta recommends patients to ask four questions when planning a colonoscopy
"Most people focus on the dislike of the preparation, the need to arrange transportation and the fear of being anesthetized during the procedure and then potentially getting a cancer diagnosis," says Neil Gupta, MD, MPH, Director of Endoscopy at Loyola University Health System. "Screening colonoscopy is a very critical examination that really can determine life and death when it comes to colon cancer. It is now clear that not every colonoscopy is equal. Once you've decided it's time to get a screening colonoscopy, the next step is to make sure that you get a high-quality one."
New analytical technology could improve cancer treatment by establishing ideal dosing regimens
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond. Using mass spectrometry, an analytical instrument for sensitive detection and accurate
Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints
Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.
January is Glaucoma Awareness Month - GRF shares information about sight-stealing disease
January is National Glaucoma Awareness Month, an important time to spread the word about this sight-stealing disease.
› Verified 6 days ago
Physical Therapists
Occupational Therapists
Optometrists
Speech-Language Pathologists
Chiropractors
Podiatrists